Genocea Biosciences Inc. buy Reibach111
Summary
This prediction ended on 03.06.19 with a price of €9.37. The BUY prediction by Reibach111 for Genocea Biosciences Inc. saw massive gains of 70.19%. Reibach111 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | 1.598% | 5.040% | 3.870% | 50.231% |
| iShares Nasdaq 100 | 3.742% | 14.947% | 36.139% | 101.082% |
| iShares Nikkei 225® | 3.736% | 13.892% | 43.808% | 69.384% |
| iShares S&P 500 | 1.816% | 8.879% | 25.510% | 70.971% |
Comments by Reibach111 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Reibach111 stimmt der Buy-Einschätzung von foxxone zu
Reibach111 stimmt am 13.03.2019 der Buy-Einschätzung von foxxone mit dem Kursziel 1$ zu.
Überschrift: Genocea Biosciences
Stopped prediction by Reibach111 for Genocea Biosciences Inc.
Genocea Biosciences Inc.
08.03.18
10.09.18
10.09.18
